We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
+2.73%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
+$52.4M
Cap. Flow
+$58.8M
Cap. Flow %
22.5%
Top 10 Hldgs %
57.88%
Holding
36
New
13
Increased
9
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$15.6M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.6M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$13.8M
5
BIIB icon
Biogen
BIIB
+$12.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$16.5M
2
MRK icon
Merck
MRK
+$14.8M
3
FOLD
Amicus Therapeutics
FOLD
+$13.4M
4
ROIV icon
Roivant Sciences
ROIV
+$11.2M
5
PFE icon
Pfizer
PFE
+$7.63M

Sector Composition

Rank Sector Weight
1 Healthcare 99.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$123B
$24.2M 9.27%
446,900
+306,900
+219% +$15.6M
GILD icon
2
Gilead Sciences
GILD
$165B
$19.4M 7.43%
+265,436
New +$20.4M
TEVA icon
3
Teva Pharmaceuticals
TEVA
$36.1B
$16M 6.13%
1,135,710
+74,042
+7% +$933K
REGN icon
4
Regeneron Pharmaceuticals
REGN
$70.5B
$15.7M 6.02%
+16,360
New +$15.6M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.4B
$15.3M 5.84%
175,000
+45,094
+35% +$4.04M
IONS icon
6
Ionis Pharmaceuticals
IONS
$8.75B
$12.5M 4.8%
+289,366
New +$13.8M
RPRX icon
7
Royalty Pharma
RPRX
$25.4B
$12.5M 4.78%
411,540
+41,540
+11% +$1.22M
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.78B
$12.2M 4.67%
+94,379
New +$11.6M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.3B
$12.2M 4.66%
658,409
+327,436
+99% +$8.11M
BIIB icon
10
Biogen
BIIB
$29.5B
$11.2M 4.29%
+52,000
New +$12.2M
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.32B
$10.7M 4.09%
2,105,459
+583,647
+38% +$3.28M
HALO icon
12
Halozyme
HALO
$9.14B
$10.4M 3.97%
255,049
+14,601
+6% +$547K
PRGO icon
13
Perrigo
PRGO
$1.47B
$10.4M 3.96%
322,114
+62,114
+24% +$1.96M
EXEL icon
14
Exelixis
EXEL
$14B
$9.46M 3.62%
398,762
-63,543
-14% -$1.41M
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$9.15M 3.5%
+541,926
New +$8.07M
LLY icon
16
Eli Lilly
LLY
$1.02T
$8.59M 3.28%
+11,040
New +$7.86M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$2.38B
$8.44M 3.23%
+288,580
New +$7.73M
CRSP icon
18
CRISPR Therapeutics
CRSP
$4.63B
$8.19M 3.13%
120,185
+12,685
+12% +$908K
ACLX
19
DELISTED
Arcellx
ACLX
$7.44M 2.85%
+107,000
New +$6.79M
INSM icon
20
Insmed
INSM
$23.2B
$6.17M 2.36%
227,337
-186,162
-45% -$5.21M
VRDN icon
21
Viridian Therapeutics
VRDN
$2.05B
$4.88M 1.87%
278,638
-29,083
-9% -$564K
LEGN icon
22
Legend Biotech
LEGN
$4.49B
$4.48M 1.71%
+79,830
New +$4.81M
KYTX icon
23
Kyverna Therapeutics
KYTX
$440M
$4.14M 1.58%
+166,514
New +$4.65M
PLRX icon
24
Pliant Therapeutics
PLRX
$66.3M
$2.89M 1.11%
+194,119
New +$3.2M
CABA icon
25
Cabaletta Bio
CABA
$448M
$2.69M 1.03%
157,964
-72,036
-31% -$1.55M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Cutter Capital Management held 36 positions worth $262M, up 25% from $209M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Cutter Capital Management deployed $58.8M of net new capital in Q1 2024, opening 13 new positions and adding to 9 existing holdings. Its largest new stake was Gilead Sciences: 265,436 shares worth $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $5.21M trimmed.

  • Cutter Capital Management's largest Q1 2024 buy was Gilead Sciences: 265,436 shares worth $19.4M.
  • Cutter Capital Management added most to Bristol-Myers Squibb in Q1 2024, an estimated $15.6M increase.
  • Cutter Capital Management's biggest Q1 2024 reduction was Insmed, cutting an estimated $5.21M.
  • Cutter Capital Management fully exited Amgen in Q1 2024, selling an estimated $16.5M.
  • Cutter Capital Management's ten largest holdings make up 58% of its $262M portfolio in Q1 2024.
  • Cutter Capital Management opened 13 new positions and closed 10 in Q1 2024.
  • Cutter Capital Management's portfolio value rose 25% quarter-over-quarter to $262M.

Based on Cutter Capital Management's 13F filing for Q1 2024, filed 15 May 2024.